1. Merkel C et al. Gruppo Triveneto per l'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004 Aug;127(2):476-84. 2. Groszmann RJ et al. for the Portal Hypertension Collaborative Group. Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. N Engl J Med 2005 Nov 24; 353:2254-2261 3. Jutabha R et al. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005 Apr; 128:870-81. 4.Sarin SK et al. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005 Apr; 128:797-804. 5. Garcia Pagan JC et al. Propanolol plus placebo versus propanolol plus isosorbide 5 mononitrate in the prevention of a first variceal bleed. a double blind RCT. Hepatology 2003; 37:1260-1266.Gastroenterology 2005;128:870-881,1120-1122. 6. Cecil. Compendio di Medicina Interna. 5° edizione, 2003. Verducci Editore. Pagg. 366-372 7. Conn's Current Therapy 2004. Elsevier Inc. 56° Edizione Italiana, pagg. 471-481 8. Khan S et al. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD000553. 9. Dib N. et al. Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ 2006 May 9; 174: 1433-1443
|
|
